



Original Investigation | Oncology

Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer

A Secondary Analysis of a Randomized Clinical Trial

Lisa Richters, MD; Oleg Gluz, MD, PhD; Nana Weber-Lassalle, PhD; Matthias Christgen, MD, PhD; Heinz Haverkamp, PhD; Sherko Kuemmel, MD, PhD; Mohamad Kayali, BSc; Ronald E. Kates, PhD; Eva-Maria Grischke, MD, PhD; Janine Altmüller, MD; Helmut Forstbauer, MD; Holger Thiele, MD; Michael Braun, MD, PhD; Mathias Warm, MD, PhD; Anna Ossowski, BSc; Rachel Wuerstlein, MD, PhD; Corinna Ernst, PhD; Monika Graeser, MD, PhD; Sabine C. Linn, MD, PhD; Ulrike Nitz, MD, PhD; Jan Hauke, PhD; Hans Heinrich Kreipe, MD, PhD; Rita K. Schmutzler, MD, PhD; Eric Hahnen, PhD; Nadia Harbeck, MD, PhD

Abstract

IMPORTANCE Subgroup definitions for possible deescalation of neoadjuvant cancer treatment are urgently needed in clinical practice.

OBJECTIVE To investigate the effect of *BRCA1* and/or *BRCA2* tumor pathogenic variants (tPVs) by comparing 2 deescalated neoadjuvant regimens (nab-paclitaxel plus either carboplatin or gemcitabine) on pathologic complete response (pCR), invasive disease-free survival (IDFS), and overall survival (OS) of patients with early-stage triple-negative breast cancer (TNBC).

DESIGN, SETTING, AND PARTICIPANTS This was a preplanned secondary analysis of a phase 2 prospective randomized clinical trial (ADAPT-TN) conducted by the West German Study Group (WSG) at 45 sites in Germany between June 2013 and February 2015. The trial enrolled patients with noninflammatory early-stage TNBC (clinical tumor size ≥ 1 cm; estrogen receptor and progesterone receptor expression $<1\%$; and *ERBB2* negative). DNA samples from pretreatment biopsies were obtained. Genetic analysis was performed between January 2018 and March 2020. Final data analyses took place in September 2023.

EXPOSURE Patients were randomized to 12 weeks of treatment with nab-paclitaxel plus either carboplatin or gemcitabine; omission of otherwise mandatory anthracycline-containing chemotherapy was allowed in the case of pCR. tPVs in 20 cancer-associated genes, including *BRCA1* and *BRCA2*, were analyzed using a customized gene panel.

MAIN OUTCOMES AND MEASURES The prevalence of *BRCA1* and/or *BRCA2* tPVs and their effect on pCR rate, IDFS, and OS were evaluated using logistic and Cox proportional hazards regression.

RESULTS Of the 307 patients with DNA samples from pretreatment biopsies available, tumor next-generation sequencing analyses were successful for 266 patients. The 266 patients included in this analysis were female, with a median age of 51 years (range, 26-76 years). A total of 162 patients (60.9%) had a clinical tumor size of 2 cm or greater, and 70 (26.3%) had clinical node-positive disease. *BRCA1* and/or *BRCA2* tPVs were detected in 42 patients (15.8%). The highest pCR rate among patients with *BRCA1* and/or *BRCA2* tPVs was seen in the nab-paclitaxel plus carboplatin group (9 of 14 patients [64.3%]) compared with the nab-paclitaxel plus gemcitabine group (10 of 28 [35.7%]) (odds ratio, 3.24 [95% CI, 0.85-12.36]; $P = .08$); the highest numeric 5-year IDFS and OS rates (84.4% and 92.9%, respectively) were seen in the nab-paclitaxel plus carboplatin group.

(continued)

Key Points

Question Are tumor pathogenic variants (tPVs) in *BRCA1* and/or *BRCA2* associated with the response to deescalated neoadjuvant nab-paclitaxel plus either carboplatin or gemcitabine among patients with early-stage triple-negative breast cancer (TNBC)?

Findings This secondary analysis of a randomized clinical trial investigated tumor next-generation sequencing data of 266 patients with early-stage TNBC who received a deescalated neoadjuvant anthracycline-free approach of nab-paclitaxel plus either gemcitabine or carboplatin. The numerically highest pathologic complete response rate of 64% was observed among patients with *BRCA1* and/or *BRCA2* tPVs who received carboplatin.

Meaning These findings suggest that *BRCA1*-tPV and/or *BRCA2*-tPV status might be a promising stratification marker for chemotherapy deescalation in early-stage TNBC.

+ Visual Abstract

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY-NC-ND License, which does not permit alteration or commercial use, including those for text and data mining, AI training, and similar technologies.

Abstract (continued)

CONCLUSIONS AND RELEVANCE In this secondary analysis of the WSG-ADAPT-TN randomized clinical trial on tPVs, deescalated nab-paclitaxel plus carboplatin was superior to nab-paclitaxel plus gemcitabine, particularly in patients with *BRCA1* and/or *BRCA2* tPVs. These findings suggest that *BRCA1* and/or *BRCA2* tPV status could be a candidate marker for a deescalation strategy in early-stage TNBC; however, prospective validation of survival outcomes in larger cohorts with differentiation between germline and somatic pathogenic variants is necessary.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: [NCT01815242](https://clinicaltrials.gov/ct2/show/study/NCT01815242)

JAMA Network Open. 2025;8(2):e2461639. doi:10.1001/jamanetworkopen.2024.61639

Introduction

Triple-negative breast cancer (TNBC) is an aggressive disease defined by the lack of estrogen receptor (ER) and progesterone receptor (PR) expression, as well as the absence of *ERBB2* (formerly *HER2*) amplification, accounting for 10% to 20% of all breast cancer cases.^{1,2} Due to the lack of therapeutic targets, antihormonal and *ERBB2*-directed approaches are ineffective. Therefore, early-stage TNBC is usually treated with chemotherapy, preferably in the neoadjuvant setting (NACT).^{3,4} Pathologic complete response (pCR) after NACT is associated with a favorable survival outcome in TNBC^{5,6} and represents an important stratification factor in the selection of further post-neoadjuvant therapies.^{7,8} Despite the promising introduction of poly(ADP-ribose) polymerase (PARP) inhibitors⁸ and immune checkpoint inhibitors,⁹ chemotherapy, especially as NACT, remains a therapeutic key component in the treatment of early-stage TNBC. Beyond the immunohistochemical conformity, TNBC is a highly heterogeneous disease¹⁰ and shows a correlation with hereditary cause.^{2,11} In unselected TNBC, the prevalence of germline pathogenic variants (gPVs) in *BRCA1* and/or *BRCA2* (hereinafter *BRCA1/2*), which are crucial in homologous recombination and DNA double-strand repair, is in the range of 9% to 18%.¹²⁻¹⁷ As DNA-intercalating substances inducing double-strand breaks, platinum derivatives have been the focus of ongoing research in TNBC. Previous clinical trials demonstrated a superior pCR rate when platinum is combined with current standard components (anthracyclines, usually combined with cyclophosphamide, and taxanes).¹⁸⁻²⁰ In the GeparSixto and BrighTNess trials, the addition of carboplatin also led to increased disease-free survival (DFS) and event-free survival (EFS) rates in early-stage TNBC²¹⁻²³; however, the CALGB 40603 trial could not confirm the EFS benefit of carboplatin,²⁴ and none of the aforementioned trials could prove a benefit for overall survival (OS).²⁵ Regarding *BRCA1/2*-associated breast cancer, carboplatin did not improve pCR rate in subgroup analyses of the GeparSixto,²⁶ BrighTNess,^{18,27} and GeparOLA²⁸ trials.

Currently, anthracycline-cyclophosphamide followed by carboplatin combined with taxane is the preferred regimen in stage 2 to 3 TNBC.²⁹ Because the potential clinical benefit comes with a risk of higher toxicity,^{25,30,31} the short-term and long-term adverse effects of these potent agents cannot be overlooked. To avoid overtreatment, the identification of predictive biomarkers for possible deescalation, as well as the optimal regimen for patients with stage 1 TNBC, should be further investigated.

The ADAPT-TN prospective randomized clinical trial, conducted by the West German Study Group (WSG), compared 4 cycles of nab-paclitaxel plus carboplatin (n = 154) with nab-paclitaxel plus gemcitabine (n = 182) for early-stage TNBC, investigating pCR as the primary end point.³² This deescalated, anthracycline-free neoadjuvant approach allowed the omission of standard anthracycline-cyclophosphamide-containing adjuvant chemotherapy if pCR was achieved. A statistically significant improvement in pCR was observed in the carboplatin group (45.9% vs 28.7%).³² Although pCR was associated with superior survival,³³ the beneficial effect of carboplatin on pCR did not translate into 5-year invasive DFS (IDFS) and OS.³⁴ This preplanned secondary analysis of the WSG-ADAPT-TN trial aimed to determine whether detecting pathogenic variants (PVs)

in *BRCA1/2* within tumor tissue could identify a subgroup of patients benefitting from carboplatin. This is of special interest because the design of the WSG-ADAPT-TN trial offers important insights into the effect of carboplatin without simultaneous or prior use of anthracycline-cyclophosphamide.

Methods

The WSG-ADAPT-TN phase 2 randomized clinical trial enrolled 336 patients with operable early-stage TNBC (clinical tumor size ≥ 1 cm without inflammatory cancer [cT1c-cT4c]; clinical node positive [cN+] or negative [cN0]; ER/PR expression $< 1\%$; and *ERBB2* negative; confirmed by central pathology) at 45 study sites in Germany between June 2013 and February 2015.³²⁻³⁴ The trial protocol is presented in [Supplement 1](#). The responsible ethics committees or institutional review boards and federal authorities approved the study, including all procedures and translational research. Written informed consent was obtained from every study participant. This secondary analysis followed the Consolidated Standards of Reporting Trials ([CONSORT](#)) reporting guideline.

Primary Outcomes

Patients in the WSG-ADAPT-TN trial were randomized to 12 weeks of NACT with nab-paclitaxel (125 mg/m² given on days 1 and 8 every 3 weeks) combined with either gemcitabine (1000 mg/m² given on days 1 and 8 every 3 weeks; n = 182) or carboplatin (area under the curve AUC2 dosing given on days 1 and 8 every 3 weeks; n = 154). For 324 participants, pCR status was assessed (eFigure 1 in [Supplement 2](#)). The primary end point was pCR (ypT0/is, ypN0) rate, evaluated after surgery according to local standards or, in the case of expected residual tumor, by confirmational biopsy (non-pCR; n = 30). If pCR was achieved, the mandatory adjuvant anthracycline-cyclophosphamide-containing chemotherapy could be omitted. Secondary end points were IDFS (defined as time from randomization until any invasive cancer-related event or death), OS, and translational parameters, including *BRCA1/2*-tumor pathogenic variant (tPV) status. Pseudonymized clinical data were collected by the WSG and centrally stored.

DNA Isolation and Next-Generation Sequencing

The isolation of DNA derived from entire formalin-fixed paraffin-embedded (FFPE) pretreatment tumor biopsies was performed using the Maxwell RSC DNA FFPE Kit (Promega) at the WSG central pathology laboratory (Institute of Pathology, University Hospital Hannover, Hannover, Germany). DNA samples were centrally analyzed at the Center for Familial Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany, using the customized TruRisk V2 gene panel (Agilent). Target enrichment was performed applying the SureSelect XT low-input FFPE-optimized protocol according to manufacturer recommendations. The input DNA was sheared using a Bioruptor Pico device (Diagenode). For next-generation sequencing (NGS), a HiSeq4000 sequencing device (Illumina) was used.

An overview of the analyzed genes and a description of the bioinformatic analyses and variant classification are presented in the eMethods in [Supplement 2](#). NGS analysis and variant classification was performed from January 2018 through February 2020.

Statistical Analysis

Categorical data were compared using the χ^2 or Fisher exact test as appropriate. Continuous data were compared using the 2-sample Wilcoxon test with continuity correction. IDFS and OS are displayed using Kaplan-Meier plots and compared using the log-rank test. $P < .05$ (2-tailed) indicated statistical significance without adjusting for multiple comparisons.

tPVs were assessed for their association with pCR, IDFS, and OS using logistic and Cox proportional hazards regression, respectively, for all patients combined and for both treatment groups separately. The clinical model for multivariable analysis is described in the eMethods in

Supplement 2. Data analysis was performed using SAS, version 9.4 (SAS Institute). Final data analyses took place in September 2023.

Results

Study Sample

Due to low DNA amounts (<10 ng), 24 of the 307 available DNA samples of pretreatment biopsies were not sequenced (baseline characteristics of all 307 patients are presented in eTable 1 in Supplement 2). In 17 samples, the sequencing output failed quality control (eFigure 1 in Supplement 2). NGS analyses of tumor samples from 266 patients with early-stage TNBC were successful, and these patients were included in this secondary analysis. All 266 patients were female, with a median age of 51 years (range, 26-76 years) (Table 1 and eTable 1 in Supplement 2). A total of 158 patients (59.4%) were treated with nab-paclitaxel plus gemcitabine and 108 (40.6%) were treated with nab-paclitaxel plus carboplatin (hereinafter referred to as the gemcitabine and carboplatin groups). Of the 266 patients, 162 (60.9%) had a clinical tumor size of 2 cm or greater, and 70 (26.3%) had cN-positive disease.

Compared with patients without available tPV assessment (eTable 1 in Supplement 2), the analyzed subcohort had significantly more frequent basal-like TNBC according to PAM50 (prediction analysis of microarray 50) subtype³³ (225 of 264 [85.2%] vs 25 of 36 [69.4%]; $P = .04$), with higher Ki67 levels (mean [SD], 68.4% [21.4] vs 58.1% [22.2]; $P < .001$). In addition, these patients more often were treated with gemcitabine (158 of 266 [59.4%] vs 24 of 70 [34.3%]; $P < .001$).

Prevalence and Genotype-Phenotype Correlation of *BRCA1/2* tPVs

BRCA1/2 tPVs were present in 42 of 266 patients (15.8%) with TNBC (Table 2 and eTable 2 in Supplement 2). Compared with patients with *BRCA1/2* wild type (WT), patients with *BRCA1/2* tPV were significantly younger (median age, 46.5 [range, 29-67] vs 53.0 [range, 26-76] years; $P = .001$) and more often were premenopausal (28 of 42 [66.7%] vs 97 of 224 [43.3%]; $P = .02$). All other characteristics were well balanced (Table 1).

pCR Rate According to *BRCA1/2*-tPV Status

Overall, 19 of 42 patients (45.2%) with *BRCA1/2* tPV had a pCR, compared with 77 of 224 patients (34.4%) without *BRCA1/2* tPV (odds ratio [OR], 1.58 [95% CI, 0.81-3.07]; $P = .18$). The *BRCA1/2*-tPV carboplatin group had a significantly higher pCR rate (9 of 14 [64.3%]) than all others pooled together (*BRCA1/2*-tPV gemcitabine and *BRCA1/2* WT in both groups; 87 of 252 [34.5%]; OR, 3.41 [95% CI, 1.11-10.50]; $P = .02$). The direct comparison with *BRCA1/2*-tPV gemcitabine (10 of 28 [35.7%]; OR, 3.24 [95% CI, 0.85-12.36]; $P = .08$) and *BRCA1/2*-WT carboplatin (45 of 94 [47.9%]; OR, 1.96 [95% CI, 0.61-6.29]; $P = .26$) showed a numeric benefit but was not statistically significant (Figure 1).

Multivariable analyses identified clinical tumor size, Ki67, and treatment group as relevant factors for the clinical model. Within the gemcitabine group, age was selected additionally; within the carboplatin group, only Ki67 remained relevant (eTable 4 in Supplement 2). The model confirmed the aforementioned findings, showing an OR greater than 1 for *BRCA1/2* tPVs in favor of achieving pCR after gemcitabine, with wide CIs (OR, 2.34 [95% CI, 0.88-6.19]; $P = .09$). The results were attenuated for the entire cohort (OR, 1.87 [95% CI, 0.87-4.00]; $P = .11$) and for the carboplatin group (OR, 1.47 [95% CI, 0.41-5.21]; $P = .55$) (eTable 5 in Supplement 2).

Survival According to *BRCA1/2*-tPV Status

The median follow-up time was 60 months (IQR, 54-62 months). Within the analyzed subcohort, an event in terms of IDFS was observed in 64 patients; 44 patients died. Five-year IDFS rates were similar in both the gemcitabine and carboplatin groups (75.4% vs 76.3%; unadjusted hazard ratio [HR], 0.95 [95% CI, 0.57-1.56]; $P = .83$) and comparable with those of the entire study cohort.³⁴

The *BRCA1/2*-tPV and *BRCA1/2*-WT subgroups showed similar 5-year IDFS rates (77.1% vs 75.4%; unadjusted HR, 0.91 [95% CI, 0.45-1.83]; $P = .78$). When separated by regimen (**Figure 2A**), patients with *BRCA1/2* tPV showed the numerically highest IDFS rate after carboplatin treatment compared with gemcitabine treatment (84.4% vs 74.1%; unadjusted HR, 0.54 [95% CI, 0.11-2.60]; $P = .44$). No difference between carboplatin vs gemcitabine treatment occurred in the *BRCA1/2*-WT cohort (75.2% vs 75.7%; unadjusted HR, 1.02 [95% CI, 0.60-1.74]; $P = .94$).

Patients with *BRCA1/2*-tPV treated with carboplatin had the highest 5-year OS rate (Figure 2B) compared with the *BRCA1/2*-tPV gemcitabine group (92.9% vs 81.0%; unadjusted HR, 0.41 [95% CI,

Table 1. Baseline Characteristics of Patients According to *BRCA1/2*-tPV Status

	Patient group			
Characteristic ^a	Total (N = 266)	BRCA1/2-WT (n = 224)	BRCA1/2-tPV (n = 42)	P value
Age at registration, y				
Median (IQR)	51.0 (43-61)	53.0 (44-62)	46.5 (37-53)	.001 ^b
Mean (SD)	51.5 (11.8)	52.5 (11.8)	46.0 (10.3)	
Menopausal status				
Postmenopausal	127 (47.7)	115 (51.3)	12 (28.6)	.02 ^c
Premenopausal	125 (47.0)	97 (43.3)	28 (66.7)	
Unknown or unclear	14 (5.3)	12 (5.4)	2 (4.8)	
Clinical tumor size				
1	104 (39.1)	89 (39.7)	15 (35.7)	.75 ^c
2	145 (54.5)	120 (53.6)	25 (59.5)	
3-4	17 (6.4)	15 (6.7)	2 (4.8)	
Clinical nodal status				
0	196 (73.7)	161 (71.9)	35 (83.3)	.30 ^c
1	61 (22.9)	55 (24.6)	6 (14.3)	
2-3	9 (3.4)	8 (3.6)	1 (2.4)	
Grade (central)				
2	15 (5.6)	14 (6.3)	1 (2.4)	.48 ^d
3	251 (94.4)	210 (93.8)	41 (97.6)	
Ki67 (primary, central), % ^e				
Median (IQR)	75 (55-85)	75 (55-85)	75 (60-80)	.96 ^b
Mean (SD)	68.4 (21.4)	68.2 (21.9)	69.4 (18.5)	
Histology (central)				
NST	262 (98.9)	220 (98.7)	42 (100)	>.99 ^d
Medullary	1 (0.4)	1 (0.4)	0	
Invasive-lobular	2 (0.8)	2 (0.9)	0	
Metaplastic	1 (0.4)	1 (0.4)	0	
PAM50 subtype ^f				
Basal	225 (85.2)	185 (83.3)	40 (95.2)	.38 ^d
ERBB2 (formerly <i>HER2</i>) enriched	15 (5.7)	14 (6.3)	1 (2.4)	
Luminal A	3 (1.1)	3 (1.4)	0	
Normal	21 (8.0)	20 (9.0)	1 (2.4)	
Treatment group ^g				
Gemcitabine	158 (59.4)	130 (58.0)	28 (66.7)	.30 ^c
Carboplatin	108 (40.6)	94 (42.0)	14 (33.3)	
pCR				
ypT0/ypN0				
No	178 (66.9)	155 (69.2)	23 (54.8)	.07 ^c
Yes	88 (33.1)	69 (30.8)	19 (45.2)	
ypT0is/ypN0				
No	170 (63.9)	147 (65.6)	23 (54.8)	.18 ^c
Yes	96 (36.1)	77 (34.4)	19 (45.2)	

Abbreviations: NST, invasive carcinoma of no special type; pCR, pathologic complete response; tPV, tumor pathogenic variant; WT, wild type.

^a Data are presented as No. (%) of patients unless otherwise indicated. Statistical tests were applied according to sample size and variable category.

^b Wilcoxon test.

^c Pearson χ^2 test.

^d Fisher exact test.

^e Data were missing for 5 patients in the *BRCA1/2*-WT group and 1 patient in the *BRCA1/2*-tPV group.

^f Data were missing for 2 patients in the *BRCA1/2*-WT group.

^g Patients were treated with nab-paclitaxel plus either carboplatin or gemcitabine.

0.05-3.54]; $P = .42$). The *BRCA1/2*-WT carboplatin group showed a numerically worse outcome than the *BRCA1/2*-WT gemcitabine group (77.8% vs 82.8%; unadjusted HR, 1.18 [95% CI, 0.62-2.23]; $P = .62$).

Multivariable modeling identified cN status as a relevant factor for the clinical model of IDFS and OS (eTable 4 in Supplement 2). After adjustment, effect sizes decreased, but the trend remained consistent (eTable 5 in Supplement 2).

Association of pCR With Survival

The association of pCR with IDFS, described in the entire study cohort,^{33,34} was observed in the *BRCA1/2*-WT group (5-year IDFS non-pCR vs pCR: 65.4% [95% CI, 56.7%-72.8%] vs 94.4% [95% CI, 85.7%-97.9%]; $P < .001$) and in the *BRCA1/2*-tPV group (non-pCR vs pCR: 68.5% [95% CI, 45.0%-83.6%] vs 87.2% [95% CI, 57.2%-96.7%]; $P = .11$) in a similar magnitude. Regarding OS, pCR rate was associated with improved outcome in the cohort without *BRCA1/2* tPVs (5-year OS non-pCR vs pCR: 71.9% [95% CI, 63.2%-79.0%] vs 97.0% [95% CI, 88.5%-99.3%]; $P < .001$) and with *BRCA1/2* tPVs (non-pCR vs pCR: 72.6% [95% CI, 48.8%-86.7%] vs 100% [95% CI, 100%-100%]; $P = .02$) (Figure 3).

Prevalence and Genotype-Phenotype Correlation of Non-*BRCA1/2* tPVs

Among the 266 patients, a high prevalence of *TP53* tPVs was observed (233 [87.6%]), followed by *PIK3CA* (22 [8.3%]) and *PTEN* (15 [5.6%]). tPVs in other breast cancer-associated genes were rare and no tPV was detected in 22 samples (8.3%). For an overview, see Table 2. eTable 2 in Supplement 2 provides comprehensive tPV information.

The 2 samples displaying a *CDH1* tPV were the only ones derived from invasive-lobular cancer (eFigure 2 in Supplement 2), and tPVs in *PIK3CA*, *PTEN*, or both were associated with a nonbasal-like PAM50 subtype, compared with TNBCs without these alterations (18 of 32 [56.3%] vs 21 of 232 [9.1%]; $P < .001$).

pCR Rate According to Non-*BRCA1/2* tPVs

An overview of the pCR rate according to tPVs in non-*BRCA1/2* genes is given in eTable 3 in Supplement 2 (multivariable analyses are detailed in eTable 5 in Supplement 2). *TP53* tPVs did not have a substantial effect on pCR in our cohort. There was an indication for a deleterious effect of *PIK3CA* tPVs; however, the results were not statistically significant ($n = 22$; all: pCR rate, 18.2%; OR, 0.28 [95% CI, 0.07-1.08]; $P = .06$).

Table 2. Prevalence of tPVs in Breast Cancer Risk Genes

Gene	No. (%) of samples (N = 266) ^a
<i>BRCA1/2</i> tPVs	
<i>BRCA1</i> ^b	37 (13.9)
<i>BRCA1</i> and <i>BRCA2</i>	2 (0.8)
<i>BRCA2</i>	3 (1.1)
All <i>BRCA1/2</i>	42 (15.8)
tPVs in non- <i>BRCA1/2</i> genes	
<i>TP53</i> ^c	233 (87.6)
<i>PIK3CA</i> ^d	22 (8.3)
<i>PTEN</i>	15 (5.6)
<i>PALB2</i> ^e	5 (1.9)
<i>BARD1</i>	3 (1.1)
<i>FANCM</i>	3 (1.1)
<i>CDH1</i>	2 (0.8)
<i>CHEK2</i>	2 (0.8)
<i>RAD50</i>	1 (0.4)
<i>RAD51C</i>	1 (0.4)
<i>RAD51D</i>	1 (0.4)
<i>STK11</i>	1 (0.4)
<i>XRCC2</i>	1 (0.4)
<i>MAP3K1</i>	1 (0.4)

Abbreviation: tPV, tumor pathogenic variant.

^a Because several samples harbored multiple tPVs, these samples are counted for each respective gene and therefore multiple referenced. No tPVs were identified in *ATM*, *BRIP1*, *MRE11A*, and *NBN*.


^b One patient carried 2 distinct *BRCA1* tPVs.

^c One sample displayed 2 distinct *TP53* tPVs.

^d One sample displayed 2 distinct *PIK3CA* tPVs.

^e One sample displayed 2 distinct *PALB2* tPVs.

Figure 1. Pathologic Complete Response (pCR) Rate According to *BRCA1/2*-Tumor Pathogenic Variant (tPV) Status Overall and in Both Treatment Groups



OR indicates odds ratio; WT, wild type.

Survival According to Non-*BRCA1/2* tPVs


TP53 tPVs were associated with worse 5-year IDFS compared with *TP53* WT (74.0% vs 87.4%; HR, 2.81 [95% CI, 1.02-7.78]; *P* = .046). There was no statistically significant effect for *PIK3CA* tPVs (56.1% vs 77.6%; HR, 1.61 [95% CI, 0.79-3.28]; *P* = .19). For OS, the associations were similar but less distinct. More detailed information is presented in the eResults and eTable 5 in Supplement 2.

Discussion

The WSG-ADAPT-TN trial assessed the effect of nab-paclitaxel plus either carboplatin or gemcitabine as deescalated NACT in early-stage TNBC. pCR was the primary end point, which provided the opportunity to examine the effect of carboplatin without the simultaneous or previous use of anthracyclines. In this preplanned exploratory substudy, we investigated the prevalence of tPVs in *BRCA1/2* and other breast cancer-associated genes and their effect on pCR and survival outcomes.

The highest pCR rate (9 of 14 patients [64.3%]) was seen in the *BRCA1/2*-tPV carboplatin group. This finding was statistically significant when compared with all others of the analyzed cohort, but


Figure 2. Survival According to *BRCA1/2*-Tumor Pathogenic Variant (tPV) Status and Treatment Group



not when compared with the *BRCA1/2*-tPV gemcitabine group (10 of 28 [35.7%]) or the *BRCA1/2*-WT carboplatin group (45 of 94 [47.9%]) directly. The *BRCA1/2*-tPV gemcitabine-treated group tended to have a higher pCR rate compared with the *BRCA1/2*-WT group (24.6%), which might be explained by higher chemosensitivity of *BRCA1/2*-associated TNBCs in general.^{35,36} Whether this effect was based on nab-paclitaxel or gemcitabine remains unclear. Likewise, 5-year IDFS and OS rates were highest in the *BRCA1/2*-tPV carboplatin-treated group, although they were not statistically significant.

Previous clinical trials provide insights on the effect of *BRCA1/2* PVs on carboplatin response. Within the GeparSixto trial, the addition of carboplatin to a dose-dense anthracycline-taxane/bevacizumab regimen improved pCR rate (43% vs 53%) in early-stage TNBC¹⁹ and led to significantly superior DFS (76% vs 86%).²¹ Patients carrying a *BRCA1/2* gPV had comparable pCR rates in both treatment groups (67% vs 65%), which was explained by saturation due to the DNA-damaging effect of anthracycline.³⁷ No notable benefit of carboplatin regarding 3-year survival was observed in the *BRCA1/2*-gPV group.

Figure 3. Effect of Pathologic Complete Response (pCR) on Survival in the *BRCA1/2*-Wild Type (WT) and *BRCA1/2*-Tumor Pathogenic Variant (tPV) Cohorts



In the BrighTNess trial,¹⁸ the addition of carboplatin with veliparib (treatment arm A) or without veliparib (treatment arm B) to a standard anthracycline-cyclophosphamide-taxane-containing regimen (treatment arm C) led to a beneficial pCR rate (57% [arm A] and 50% [arm B] vs 41% [arm C] in *BRCA1/2*-gPV subgroups), which was independent of *BRCA1/2* gPV status.²⁷ pCR was associated with improved DFS in patients with *BRCA1/2* gPV and *BRCA1/2* WT.²³ Within the GeparOLA study, patients with *BRCA1/2*-gPV or homologous recombination deficient, *ERBB2*-negative breast cancer received standard or dose-dense taxane combined with carboplatin vs PARP inhibitors, followed by anthracycline-cyclophosphamide.²⁸ This resulted in a pCR rate of 60% in both groups for patients with *BRCA1/2* tPV.²⁸

Even in the absence of anthracycline, the pCR rate we observed in the small *BRCA1/2*-tPV group treated with deescalated nab-paclitaxel plus carboplatin was similarly high in this study compared with that in *BRCA1/2*-associated breast cancers treated with carboplatin added to standard or dose-dense anthracycline-taxane treatment (with or without cyclophosphamide) in the aforementioned trials. Although the GeparOLA baseline characteristics were similar,²⁸ patients with locally more advanced disease were included in the BrighTNess and GeparSixto trials.^{19,21} Therefore, this cross-trial comparison should be interpreted with caution.

In escalated treatment of high-risk early-stage TNBC, carboplatin has become a standard combination agent for anthracycline-cyclophosphamide-taxane and pembrolizumab, according to the pivotal KEYNOTE-522 trial.^{9,38} This is of special interest because the PARP inhibitor olaparib can be a relevant option in (post-neo)adjuvant treatment of *BRCA1/2*-gPV-associated breast cancer, whereas its effect on survival was attenuated after platinum within the OlympiA trial.⁸ However, when comparing the results of our trial and other trials, it remains unclear whether a completion of a 24-week regimen is necessary in case a pCR is achieved after 12 weeks of taxane treatment combined with carboplatin. Our results allow the presumption that *BRCA1/2* tPV status might be a stratification factor for deescalated, shorter treatment regimens in case of favorable prognostic conditions (eg, cNO and pCR).

In concordance with the results of the BrighTNess trial,²³ our findings can support the hypothesis that pCR is a surrogate marker for survival in patients with *BRCA1/2* tPVs. However, the association was only observed for OS, and survival outcomes were only secondary end points.

Because adjuvant anthracycline-cyclophosphamide was mandatory in case of non-pCR but optional after pCR, this analysis cannot clarify whether anthracycline-cyclophosphamide can be omitted in the *BRCA1/2*-tPV group treated with carboplatin despite the high survival rate. In the main WSG-ADAPT-TN trial, anthracycline-cyclophosphamide after pCR did not alter IDFS risk,³⁴ which was in line with the small phase 2 NEOCART trial showing superior pCR (61% vs 39%) and equivalent EFS and OS rates after 37 months when comparing 6 cycles of carboplatin-docetaxel with an anthracycline-cyclophosphamide-taxane regimen in early-stage TNBC.³⁹ Because IDFS events in this subset in our analysis were rare (8 of 96 patients with pCR), this aspect needs to be addressed in future investigations.

In an exploratory, hypothesis-generating approach, we assessed the effects of tPVs in non-*BRCA1/2* genes on clinical outcome. The numerically worse outcome of patients with a *PIK3CA* tPV is in line with previous reports of chemotherapy resistance and low response rates to NACT in early-stage TNBC harboring somatic *PIK3CA* PVs.^{40,41} Because targeted approaches might be promising, several clinical trials with *PIK3CA*-directed agents are ongoing in advanced TNBC.⁴²

In this analysis, patients without *TP53* tPVs showed a favorable survival. In a secondary analysis of the GeparSixto trial,⁴³ no effect of *TP53* tPVs on survival in the early-stage TNBC subgroup was observed, whereas earlier data showed a superior outcome of basal-like BCs with *TP53* tPVs when treated with dose-dense anthracycline-cyclophosphamide.^{44,45}

Limitations

This study has some limitations. Because the overall study was not powered for this exploratory approach with small genetic subgroups, the findings often were not statistically significant even when large effects were observed.

Due to the retrospective explorative character of the analysis, moderate imbalances were observed in baseline characteristics regarding higher rates of basal-like TNBC, higher Ki67 levels, and a greater proportion of patients treated with gemcitabine in the analyzed subcohort compared with those not analyzed. Whereas the pCR and IDFS rates were comparable with those of the whole study cohort, a more balanced ratio of treatment groups would have strengthened the statistical power to estimate the effect of carboplatin.

Also, survival was a secondary end point, not the focus of the trial design, and the unclear role of adjuvant anthracycline-cyclophosphamide treatment allows only a vague interpretation of survival data. The events in the *BRCA1/2*-tPV group were rare (OS: *n* = 6; and IDFS: *n* = 9), limiting the statistical power.

Furthermore, we did not perform mutual genetic germline testing, which made the differentiation of gPVs from somatic PVs impossible. Approximately 1% of patients with familial breast cancer carry germline large genomic rearrangements in *BRCA1/2*,⁴⁶ which were not detected by the method applied in this study. The DNA amount of the samples was limited and in several cases was below or close to 10 ng, leading to a high dropout rate. Because entire biopsies were processed, the tumor cell count was unclear, whereas the prevalence of tPVs in *BRCA1/2* and *TP53* was in line with previous findings,⁴⁷⁻⁵¹ indicating that the detection of tPVs was generally sufficient.

Conclusions

In this secondary analysis of a randomized clinical trial of patients with early-stage TNBC, deescalated neoadjuvant nab-paclitaxel plus carboplatin was highly effective and superior to nab-paclitaxel plus gemcitabine. Although a beneficial pCR rate was observed in both the *BRCA1/2*-WT and *BRCA1/2*-tPV subgroups, the effect was more distinct in the latter and possibly translated into improved survival. To prevent overtreatment, *BRCA1/2* tPV status may thus be a useful stratification factor for chemotherapy deescalation. Larger prospective randomized trials, designed for survival end points, are necessary. Possible combinations with PARP inhibitors and immune checkpoint inhibitors in deescalation, as well as the comparison of these potent agents alone^{52,53} vs deescalated NACT in *BRCA1/2*-associated early-stage TNBC, should be evaluated. Moreover, the effect of germline vs somatic PVs in *BRCA1/2* as predictive factors and the relevance of PVs in other breast cancer-associated genes should be further investigated.

ARTICLE INFORMATION

Accepted for Publication: December 9, 2024.

Published: February 26, 2025. doi:10.1001/jamanetworkopen.2024.61639

Open Access: This is an open access article distributed under the terms of the [CC-BY-NC-ND License](#), which does not permit alteration or commercial use, including those for text and data mining, AI training, and similar technologies. © 2025 Richters L et al. *JAMA Network Open*.

Corresponding Author: Lisa Richters, MD, Center for Familial Breast and Ovarian Cancer and Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Kerpener Str. 62, Gebäude 70, 50937 Cologne, Germany (lisa.richters@uk-koeln.de).

Author Affiliations: Center for Familial Breast and Ovarian Cancer, Faculty of Medicine, University Hospital Cologne, Cologne, Germany (Richters, Weber-Lassalle, Kayali, Ernst, Hauke, Schmutzler, Hahnen); Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne, Germany (Richters, Weber-Lassalle, Kayali, Ernst, Hauke, Schmutzler, Hahnen); West German Study Group, Moenchengladbach, Germany (Gluz, Kuemmel, Kates, Wuerstlein, Graeser, Nitz, Harbeck); Ev. Hospital Bethesda, Breast Center Niederrhein,

Moenchengladbach, Germany (Gluz, Graeser); Women's Clinic and Breast Center, University Clinics Cologne, Cologne, Germany (Gluz); Institute of Pathology, Medical School Hannover, Hannover, Germany (Christgen, Kreipe); Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany (Haverkamp); Now with Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany (Haverkamp); Interdisciplinary Breast Center, Kliniken Essen-Mitte, Evang. Hospital Essen-Mitte, Essen, Germany (Kuemmel); Department of Gynecology, Breast Center, Charité-Universitätsmedizin Berlin, Berlin, Germany (Kuemmel); Women's Clinic, University Clinics Tübingen, Tübingen, Germany (Grischke); Cologne Center for Genomics, University of Cologne, Cologne, Germany (Altmüller, Thiele, Ossowski); Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (Altmüller); Core Unit Genomics, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany (Altmüller); Oncology Practice Network, Troisdorf, Germany (Forstbauer); Interdisciplinary Breast Center, Rotkreuz-Clinics Munich, Munich, Germany (Braun); Breast Center, Municipal Hospital Holweide, Cologne, Germany (Warm); Breast Center, Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital of Ludwig Maximilian University, Munich, Germany (Wuerstlein, Harbeck); Department of Gynecology, University Medical Center Hamburg, Hamburg, Germany (Graeser); Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands (Linn); Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands (Linn); Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands (Linn).

Author Contributions: Drs Richters and Haverkamp had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Dr Hahnen and Prof Harbeck contributed equally to this work.

Concept and design: Richters, Gluz, Kuemmel, Kates, Grischke, Graeser, Hahnen, Harbeck.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Richters, Gluz, Weber-Lassalle, Christgen, Haverkamp, Ossowski.

Critical review of the manuscript for important intellectual content: Richters, Gluz, Haverkamp, Kuemmel, Kayali, Kates, Grischke, Altmüller, Forstbauer, Thiele, Braun, Warm, Wuerstlein, Ernst, Graeser, Linn, Nitz, Hauke, Kreipe, Schmutzler, Hahnen, Harbeck.

Statistical analysis: Richters, Gluz, Haverkamp, Kates.

Obtained funding: Nitz, Schmutzler, Harbeck.

Administrative, technical, or material support: Richters, Weber-Lassalle, Kayali, Altmüller, Thiele, Ossowski, Wuerstlein, Graeser, Nitz, Kreipe, Schmutzler, Hahnen, Harbeck.

Supervision: Richters, Gluz, Christgen, Kuemmel, Grischke, Schmutzler, Hahnen.

Conflict of Interest Disclosures: Dr Richters reported receiving personal fees and nonfinancial support from AstraZeneca outside the submitted work. Dr Gluz reported receiving grants from Celgene and nonfinancial support from Teva during the conduct of the study. In addition, Dr Gluz reported receiving personal fees from Roche, AstraZeneca, Gilead, MSD, Novartis, Pfizer, Lilly, Exact Science, Agendia, and Daiichi-Sankyo outside the submitted work. Dr Gluz also reported serving as co-director of the West German Study Group (WSG). Prof Kuemmel reported receiving personal fees for consulting or advisory board service from Novartis, Pfizer, Lilly Roche, AstraZeneca, Hologic, MSD Oncology, Agendia, Gilead, Sonoscape, Daiichi-Sankyo, Pink DiGA, Stemline, and Exact Science during the conduct of the study. In addition, Prof Kuemmel reported receiving travel support from Roche and Daiichi-Sankyo and having an uncompensated relationship with WSG outside the submitted work. Prof Wuerstlein reported receiving personal fees from Agendia, Amgen, AstraZeneca, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Hexal, Lilly, MSD, Nanostring, Novartis, Onkowsen, Paxman, Palleos, Pfizer, Pierre Fabre, PINK, Roche, Seagen, Sidekick, Stemline, Teva, Veracyte, Viatris, and Wiley during the conduct of the study. In addition, Prof Wuerstlein reported receiving grants from SPCC and personal fees from FOMF, Aurikamed, Clinsol, Pomme Med, IMED, MCI, MediSeminar, Medicultus, H+O Communications, Streamed Up, AGO, PINK!, Coach, WSG, Junge Erwachsene mit Krebs, and Brustkrebs Deutschland eV outside the submitted work. Prof Linn reported receiving institutional unrestricted research grants from AstraZeneca, Eurocept Pharmaceuticals, Roche, Agendia, GlaxoSmithKline (GSK), Gilead, and Novartis and an educational grant from Daiichi-Sankyo outside the submitted work. In addition, Prof Linn reported receiving nonfinancial support in the form of study drugs from AstraZeneca, Roche, GSK, and Novartis and diagnostic tests from Agilent and Agendia; and serving on advisory boards for AstraZeneca and Agendia (compensation paid to institute) and for Cergentis (uncompensated) outside the submitted work. Prof Linn also reported having a patent issued (EP4141127: Method for Assessing Homologous Recombination Deficiency in Ovarian Cancer Cells). Dr Hauke reported receiving grants from German Cancer Aid outside the submitted work. Prof Schmutzler reported receiving grants from the German Breast Group during the conduct of the study. Prof Harbeck reported receiving personal fees from AstraZeneca, Daiichi-Sankyo, Gilead,

Lilly, Novartis, MSD, Pierre Fabre, Pfizer, Sandoz, and Seagen and having minority ownership in WSG outside the submitted work. No other disclosures were reported.

Funding/Support: The next-generation sequencing analyses were supported by the Cologne Fortune Program, Faculty of Medicine, University of Cologne, Cologne Germany. Drug support and conduct of the study was supported by Celgene and Teva. Previous translational research was supported by Nanostring.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See [Supplement 3](#).

Additional Contributions: We thank all of the participants and their families for their contributions to this study. Additionally, we thank Palleos GmbH and WSG GmbH for trial management, as well as all study centers and pathologists, particularly the central pathology laboratory of Medizinische Hochschule Hannover, for data and tumor tissue collection.

REFERENCES

1. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. *CA Cancer J Clin*. 2022;72(6):524-541. doi:[10.3322/caac.21754](#)
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med*. 2010;363(20):1938-1948. doi:[10.1056/NEJMra1001389](#)
3. Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. *J Clin Oncol*. 2021;39(13):1485-1505. doi:[10.1200/JCO.20.03399](#)
4. Cardoso F, Kyriakides S, Ohno S, et al; ESMO Guidelines Committee. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(8):1194-1220. doi:[10.1093/annonc/mdz173](#)
5. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*. 2008;26(8):1275-1281. doi:[10.1200/JCO.2007.14.4147](#)
6. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*. 2012;30(15):1796-1804. doi:[10.1200/JCO.2011.38.8595](#)
7. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *N Engl J Med*. 2017;376(22):2147-2159. doi:[10.1056/NEJMoa1612645](#)
8. Geyer CE Jr, Garber JE, Gelber RD, et al; OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. *Ann Oncol*. 2022;33(12):1250-1268. doi:[10.1016/j.annonc.2022.09.159](#)
9. Schmid P, Cortes J, Pusztai L, et al; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. *N Engl J Med*. 2020;382(9):810-821. doi:[10.1056/NEJMoa1910549](#)
10. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. *Cancer Discov*. 2019;9(2):176-198. doi:[10.1158/2159-8290.CD-18-1177](#)
11. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. *Cancer Res*. 2013;73(7):2025-2030. doi:[10.1158/0008-5472.CAN-12-1699](#)
12. Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. *Breast Cancer Res Treat*. 2014;145(3):707-714. doi:[10.1007/s10549-014-2980-0](#)
13. Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. *Clin Epidemiol*. 2019;11:543-561. doi:[10.2147/CLEP.S206949](#)
14. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. *Clin Cancer Res*. 2011;17(5):1082-1089. doi:[10.1158/1078-0432.CCR-10-2560](#)
15. Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer. *Breast Cancer Res Treat*. 2016;158(3):455-462. doi:[10.1007/s10549-016-3902-0](#)
16. Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK. Germline mutations in triple-negative breast cancer. *Breast Care (Basel)*. 2017;12(1):15-19. doi:[10.1159/000455999](#)
17. Rhiem K, Zachariae S, Waha A, et al. Prevalence of pathogenic germline variants in women with non-familial unilateral triple-negative breast cancer. *Breast Care (Basel)*. 2023;18(2):106-112. doi:[10.1159/000528972](#)

18. Loibl S, O'Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. *Lancet Oncol*. 2018;19(4):497-509. doi:[10.1016/S1470-2045\(18\)30111-6](https://doi.org/10.1016/S1470-2045(18)30111-6)
19. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol*. 2014;15(7):747-756. doi:[10.1016/S1470-2045\(14\)70160-3](https://doi.org/10.1016/S1470-2045(14)70160-3)
20. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). *J Clin Oncol*. 2015;33(1):13-21. doi:[10.1200/JCO.2014.57.0572](https://doi.org/10.1200/JCO.2014.57.0572)
21. Loibl S, Weber KE, Timms KM, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. *Ann Oncol*. 2018;29(12):2341-2347. doi:[10.1093/annonc/mdy460](https://doi.org/10.1093/annonc/mdy460)
22. Loibl S, Sikov W, Huober J, et al. 1190 Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥ 4 years of follow-up: BrighTNess, a randomized phase III trial. *Ann Oncol*. 2021;32(suppl 5):S408. doi:[10.1016/j.annonc.2021.08.400](https://doi.org/10.1016/j.annonc.2021.08.400)
23. Geyer CE, Sikov WM, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. *Ann Oncol*. 2022;33(4):384-394. doi:[10.1016/j.annonc.2022.01.009](https://doi.org/10.1016/j.annonc.2022.01.009)
24. Shepherd JH, Ballman K, Polley MC, et al. CALGB 40603 (Alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. *J Clin Oncol*. 2022;40(12):1323-1334. doi:[10.1200/JCO.21.01506](https://doi.org/10.1200/JCO.21.01506)
25. Mason SR, Willson ML, Egger SJ, Beith J, Dear RF, Goodwin A. Platinum-based chemotherapy for early triple-negative breast cancer. *Cochrane Database Syst Rev*. 2023;9(9):CD014805. doi:[10.1002/14651858.CD014805.pub2](https://doi.org/10.1002/14651858.CD014805.pub2)
26. Dorling L, Carvalho S, Allen J, et al; Breast Cancer Association Consortium. Breast cancer risk genes: association analysis in more than 113,000 women. *N Engl J Med*. 2021;384(5):428-439. doi:[10.1056/NEJMoa1913948](https://doi.org/10.1056/NEJMoa1913948)
27. Metzger-Filho O, Collier K, Asad S, et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in BrighTNess. *NPJ Breast Cancer*. 2021;7(1):142. doi:[10.1038/s41523-021-00349-y](https://doi.org/10.1038/s41523-021-00349-y)
28. Fasching PA, Link T, Hauke J, et al; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). *Ann Oncol*. 2021;32(1):49-57. doi:[10.1016/j.annonc.2020.10.471](https://doi.org/10.1016/j.annonc.2020.10.471)
29. Sohn J, Kim GM, Jung KH, et al. A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. *J Clin Oncol*. 2024;42(17 suppl):LBA502. doi:[10.1200/JCO.2024.42.17_suppl.LBA502](https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA502)
30. Vuger AT, Tiscoski K, Apolinario T, Cardoso F. Anthracyclines in the treatment of early breast cancer friend or foe? *Breast*. 2022;65:67-76. doi:[10.1016/j.breast.2022.06.007](https://doi.org/10.1016/j.breast.2022.06.007)
31. Hirmas N, Holtschmidt J, Loibl S. Shifting the paradigm: the transformative role of neoadjuvant therapy in early breast cancer. *Cancers (Basel)*. 2024;16(18):3236. doi:[10.3390/cancers16183236](https://doi.org/10.3390/cancers16183236)
32. Gluz O, Nitz U, Liedtke C, et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. *J Natl Cancer Inst*. 2018;110(6):628-637. doi:[10.1093/jnci/djx258](https://doi.org/10.1093/jnci/djx258)
33. Gluz O, Kolberg-Liedtke C, Prat A, et al. Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: primary translational analysis of the WSG-ADAPT-TN trial. *Int J Cancer*. 2020;146(1):262-271. doi:[10.1002/ijc.32488](https://doi.org/10.1002/ijc.32488)
34. Gluz O, Nitz U, Kolberg-Liedtke C, et al; ADAPT TN investigators. De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): impact of molecular markers and final survival analysis of the WSG-ADAPT-TN trial. *Clin Cancer Res*. 2022;28(22):4995-5003. doi:[10.1158/1078-0432.CCR-22-0482](https://doi.org/10.1158/1078-0432.CCR-22-0482)
35. Pohl-Rescigno E, Hauke J, Loibl S, et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto Randomized Clinical Trial. *JAMA Oncol*. 2020;6(5):744-748. doi:[10.1001/jamaoncol.2020.0007](https://doi.org/10.1001/jamaoncol.2020.0007)

36. Mutai R, Kuchuk I, Goldshtein A, et al. The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy. *Breast Cancer Res Treat*. 2024;205(2):241-248. doi:10.1007/s10549-024-07247-4
37. Hahnen E, Lederer B, Hauke J, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. *JAMA Oncol*. 2017;3(10):1378-1385. doi:10.1001/jamaoncol.2017.1007
38. Schmid P, Cortes J, Dent R, et al; KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. *N Engl J Med*. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651
39. Zhang L, Wu ZY, Li J, et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial. *Int J Cancer*. 2022;150(4):654-662. doi:10.1002/ijc.33830
40. Hu H, Zhu J, Zhong Y, et al. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. *Ann Transl Med*. 2021;9(5):410. doi:10.21037/atm-21-698
41. Guo S, Loibl S, von Minckwitz G, Darb-Esfahani S, Lederer B, Denkert C. PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. *Cancer Res Treat*. 2020;52(3):689-696. doi:10.4143/crt.2019.497
42. Zhang HP, Jiang RY, Zhu JY, et al. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. *Breast Cancer*. 2024;31(4):539-551. doi:10.1007/s12282-024-01567-5
43. Darb-Esfahani S, Denkert C, Stenzinger A, et al. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. *Oncotarget*. 2016;7(42):67686-67698. doi:10.18632/oncotarget.11891
44. Bertheau P, Lehmann-Che J, Varna M, et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. *Breast*. 2013;22(suppl 2):S27-S29. doi:10.1016/j.breast.2013.07.005
45. Bertheau P, Turpin E, Rickman DS, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. *PLoS Med*. 2007;4(3):e90. doi:10.1371/journal.pmed.0040090
46. Lepkes L, Kayali M, Blümcke B, et al. Performance of in silico prediction tools for the detection of germline copy number variations in cancer predisposition genes in 4208 female index patients with familial breast and ovarian cancer. *Cancers (Basel)*. 2021;13(1):118. doi:10.3390/cancers13010118
47. Staaf J, Glodzik D, Bosch A, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. *Nat Med*. 2019;25(10):1526-1533. doi:10.1038/s41591-019-0582-4
48. Cancer Genome Atlas N; Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012;490(7418):61-70. doi:10.1038/nature11412
49. Heeke AL, Xiu J, Elliott A, et al. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. *Breast Cancer Res Treat*. 2020;184(2):265-275. doi:10.1007/s10549-020-05849-2
50. Mitri ZI, Abuhadra N, Goodyear SM, et al. Impact of TP53 mutations in triple negative breast cancer. *NPJ Precis Oncol*. 2022;6(1):64. doi:10.1038/s41698-022-00303-6
51. Singh A, Georgy JT, Dhananjayan S, et al. Comparative analysis of mutational patterns in triple negative breast cancer before and after neoadjuvant chemotherapy in patients with residual disease. *Gene*. 2024;895:147980. doi:10.1016/j.gene.2023.147980
52. Litton JK, Beck JT, Jones JM, et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: results of a phase II study. *Oncologist*. 2023;28(10):845-855. doi:10.1093/oncolo/oyad139
53. Balmaña J, Dymond M, Lowe ES, Lukashchuk N, Winter M, Tung N. OlympiA: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer. *Cancer Res*. 2023;83(5 suppl):OT2-18-02. doi:10.1158/1538-7445.SABCS22-OT2-18-02

SUPPLEMENT 1.

Trial Protocol

SUPPLEMENT 2.

eMethods

eResults

eFigure 1. Flow Diagram of Samples Analyzed in the Study

eFigure 2. Immunohistochemical E-Cadherin Staining

eTable 1. Baseline Characteristics of Patients With and Without Available Tumor Pathogenic Variant Assessment

eTable 2. Overview of the Detected Tumor Pathogenic Variants in All 266 Samples

eTable 3. Pathologic Complete Response Rate of Patients With Tumor Pathogenic Variants in Non-*BRCA1/2* Genes

eTable 4. Clinical Parameters Included in the Multivariable Model

eTable 5. Multivariable Modeling of Genetic Subgroups for Pathologic Complete Response, Invasive Disease-Free Survival, and Overall Survival

eReferences

SUPPLEMENT 3.

Data Sharing Statement